SCHEMBL31664555

SCHEMBL31664555

CCc1cc(=O)n2nc(C)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPT P10636 3/20 0.42
▸ FPR1 P21462 1/20 0.42
▸ FPR2 P25090 1/20 0.42
▸ LMNA P02545 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ AKR1B1 P15121 1/20 0.40
▸ TSHR P16473 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ TRPA1 O75762 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ HIF1A Q16665 1/20 0.38
▸ RORC P51449 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31713877 0.89 KDM4E (0.44) KDM4EMAPTFPR1FPR2LMNA
SCHEMBL31713855 0.87 KDM4E (0.40) KDM4EMAPTLMNATP53AKR1B1
SCHEMBL31664544 0.83 KDM4E (0.43) KDM4EMAPTFPR1FPR2LMNA
SCHEMBL31664578 0.81 KDM4E (0.43) KDM4EMAPTFPR1FPR2LMNA
SCHEMBL31713883 0.81 WRN (0.49) KDM4EMAPTLMNATP53AKR1B1
SCHEMBL31713938 0.77 KDM4E (0.41) KDM4EMAPTLMNATP53AKR1B1
SCHEMBL25035250 0.76 ACHE (0.44) KDM4EMAPTLMNATP53AKR1B1
SCHEMBL30037179 0.76 ACHE (0.44) KDM4EMAPTLMNATP53AKR1B1
SCHEMBL31664583 0.75 MAPT (0.41) KDM4EMAPTFPR1FPR2LMNA
SCHEMBL31047165 0.73 ACHE (0.47) MAPTLMNATP53TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236622-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236622-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL KDM4E 3651/4885MAPT 4634/4885FPR1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback